Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBITDA (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed EBITDA for 5 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 259.03% year-over-year to $14.3 million, compared with a TTM value of $59.1 million through Dec 2025, up 236.39%, and an annual FY2025 reading of $59.1 million, up 236.39% over the prior year.
  • EBITDA was $14.3 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $18.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $224.1 million in Q3 2022 and bottomed at -$49.5 million in Q1 2021.
  • Average EBITDA over 5 years is $2.8 million, with a median of -$10.6 million recorded in 2023.
  • The sharpest move saw EBITDA skyrocketed 832.01% in 2022, then crashed 135.69% in 2024.
  • Year by year, EBITDA stood at -$36.4 million in 2021, then skyrocketed by 112.58% to $4.6 million in 2022, then soared by 451.78% to $25.2 million in 2023, then plummeted by 135.69% to -$9.0 million in 2024, then skyrocketed by 259.03% to $14.3 million in 2025.
  • Business Quant data shows EBITDA for KNSA at $14.3 million in Q4 2025, $18.3 million in Q3 2025, and $17.9 million in Q2 2025.